Elan Targets Teva Again Over Generic Focalin XR

Law360, New York (April 26, 2011, 5:12 PM EDT) -- Elan Corp. PLC sued Teva Pharmaceuticals USA Inc. on Monday in Delaware over the generics maker's latest efforts to market its own version of attention deficit hyperactivity disorder drug Focalin XR.

The suit marks the second time Elan and Teva have gone head to head in litigation over two of the Irish pharmaceutical company's patents for the extended release version of its popular ADHD treatment, which, along with its Ritalin LA, generated $33 million in revenues for the company in 2010.

The companies settled an earlier...
To view the full article, register now.